KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Equity Average (2016 - 2025)

Historic Equity Average for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $20.6 billion.

  • Gilead Sciences' Equity Average rose 1264.66% to $20.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 billion, marking a year-over-year increase of 1264.66%. This contributed to the annual value of $21.0 billion for FY2024, which is 427.45% down from last year.
  • Gilead Sciences' Equity Average amounted to $20.6 billion in Q3 2025, which was up 1264.66% from $19.4 billion recorded in Q2 2025.
  • Gilead Sciences' Equity Average's 5-year high stood at $22.5 billion during Q4 2023, with a 5-year trough of $17.8 billion in Q2 2024.
  • For the 5-year period, Gilead Sciences' Equity Average averaged around $20.1 billion, with its median value being $20.5 billion (2022).
  • Data for Gilead Sciences' Equity Average shows a peak YoY increase of 1917.24% (in 2021) and a maximum YoY decrease of 1705.15% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Gilead Sciences' Equity Average stood at $21.3 billion in 2021, then decreased by 0.63% to $21.1 billion in 2022, then increased by 6.45% to $22.5 billion in 2023, then fell by 16.16% to $18.9 billion in 2024, then increased by 9.26% to $20.6 billion in 2025.
  • Its Equity Average was $20.6 billion in Q3 2025, compared to $19.4 billion in Q2 2025 and $19.2 billion in Q1 2025.